Ciljana terapija (Serbian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Ciljana terapija" in Serbian language version.
refsWebsite
Global rank
Serbian rank
18th place
28th place
low place
low place
dddmag.com
- „Merck, Endocyte in Development Deal”. dddmag.com. 23. 2. 2019.
doi.org
- Hanks SK, Quinn AM, Hunter T (1988). „The protein kinase family: conserved features and deduced phylogeny of the catalytic domains”. Science. 241 (4861): 42—52. Bibcode:1988Sci...241...42H. PMID 3291115. doi:10.1126/science.3291115.
- Katzel, Jed A.; Fanucchi, Michael P.; Li, Zujun (2009). „Recent advances of novel targeted therapy in non-small cell lung cancer”. Journal of Hematology & Oncology. 2: 2. PMC 2637898
. PMID 19159467. doi:10.1186/1756-8722-2-2 . - Jordan, V. Craig (2008). „Tamoxifen: Catalyst for the change to targeted therapy”. European Journal of Cancer. 44 (1): 30—38. PMC 2566958 . PMID 18068350. doi:10.1016/j.ejca.2007.11.002.
- Warr, M. R.; Shore, G. C. (2008). „Small-molecule BCL-2 antagonists as targeted therapy in oncology”. Current Oncology (Toronto, Ont.). 15 (6): 256—261. PMC 2601021 . PMID 19079626. doi:10.3747/co.v15i6.392.
- Li, Jin; Zhao, Xinmin; Chen, Lei; Guo, Haiyi; Lv, Fangfang; Jia, Ka; Yv, Ke; Wang, Fengqing; Li, Chuan; Qian, Jun; Zheng, Chunlei; Zuo, Yunxia (2010). „Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies”. BMC Cancer. 10: 529. PMC 2984425 . PMID 20923544. doi:10.1186/1471-2407-10-529 .
europa.eu
ema.europa.eu
- European medicines Agency (June 2014). “Erbitux® Summary of Product Characteristics (PDF).“ 2015-11-19.
fda.gov
- “Therascreen KRAS RGQ PCR Kit – P110030“. Device Approvals and Clearances. U.S. Food and Drug Administration. 2012-07-06.
- “Cetuximab (Erbitux). About the Center of Drug Evaluation and Research." U.S. Food and Drug Administration. 2015-11-16.
harvard.edu
adsabs.harvard.edu
- Hanks SK, Quinn AM, Hunter T (1988). „The protein kinase family: conserved features and deduced phylogeny of the catalytic domains”. Science. 241 (4861): 42—52. Bibcode:1988Sci...241...42H. PMID 3291115. doi:10.1126/science.3291115.
merck.de
nih.gov
ncbi.nlm.nih.gov
- Hanks SK, Quinn AM, Hunter T (1988). „The protein kinase family: conserved features and deduced phylogeny of the catalytic domains”. Science. 241 (4861): 42—52. Bibcode:1988Sci...241...42H. PMID 3291115. doi:10.1126/science.3291115.
- Katzel, Jed A.; Fanucchi, Michael P.; Li, Zujun (2009). „Recent advances of novel targeted therapy in non-small cell lung cancer”. Journal of Hematology & Oncology. 2: 2. PMC 2637898 . PMID 19159467. doi:10.1186/1756-8722-2-2 .
- Jordan, V. Craig (2008). „Tamoxifen: Catalyst for the change to targeted therapy”. European Journal of Cancer. 44 (1): 30—38. PMC 2566958 . PMID 18068350. doi:10.1016/j.ejca.2007.11.002.
- Warr, M. R.; Shore, G. C. (2008). „Small-molecule BCL-2 antagonists as targeted therapy in oncology”. Current Oncology (Toronto, Ont.). 15 (6): 256—261. PMC 2601021 . PMID 19079626. doi:10.3747/co.v15i6.392.
- Li, Jin; Zhao, Xinmin; Chen, Lei; Guo, Haiyi; Lv, Fangfang; Jia, Ka; Yv, Ke; Wang, Fengqing; Li, Chuan; Qian, Jun; Zheng, Chunlei; Zuo, Yunxia (2010). „Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies”. BMC Cancer. 10: 529. PMC 2984425 . PMID 20923544. doi:10.1186/1471-2407-10-529 .
- Thomas J. Kindt; Richard A. Goldsby; Barbara Anne Osborne; Janis Kuby (2006). Kuby Immunology (6 изд.). New York: W H Freeman and company. ISBN 1429202114.